would be greater than on the softer surface of fells, and were absent during cycling when passive contraction of the psoas would produce less colonic compression. This mechanism may be similar to the repetitive mechanical trauma described to explain contusion of the bladder and haematuria in runners.⁵

"Jogger's trots" is a further example of the many hazards that face marathon runners. Although our patient's symptoms may be controlled with drugs, this seems contrary to the principle of guidelines for the control of abuse of drugs in sport.

We thank Mrs S Lamb for secretarial help.

- 1 Sullivan SN. The gastrointestinal symptoms of running. *N Engl J Med* 1981;**304**: 915.
- 2 Fogoros RN. "Runner's trots." Gastrointestinal disturbances in runners. *JAMA* 1980;**243**:1743-4.
- 3 Cantwell JD. Gastrointestinal disorders in runners. *JAMA* 1981;**246**:1404-5.
- 4 Read NW, Miles CA, Fisher D, et al. Transit of a meal through the stomach, small intestine and colon in normal subjects and its role in the pathogenesis of diarrhoea. *Gastroenterology* 1980;**79**:1276-82.
- 5 Blacklock NJ. Bladder trauma in the long distance runner—"10,000 metres haematuria." *Br J Urol* 1977;**49**:129-32.

(Accepted 28 May 1985)

Department of Gastroenterology, North Manchester General Hospital, Manchester

D J DAWSON, BSC, MRCP, senior medical registrar
A N KHAN, MRCP, FRCR, consultant radiologist
D R SHREEVE, FRCP, FRCPD, consultant physician

Correspondence to: Dr D J Dawson, Department of Gastroenterology, Manchester Royal Infirmary, Manchester M13 9WL.

Double blind, placebo controlled trial of betamethasone nasal drops for nasal polyposis

The aetiology and pathogenesis of nasal polyps are poorly understood. Studies have shown no effect of topical corticosteroids on nasal polyps, although concomitant sneezing and hypersecretion of mucus were reduced.¹⁻³ We have investigated the efficacy of betamethasone drops in the treatment of nasal polyposis when administered in a position designed to increase exposure of nasal and paranasal sinus mucosa to the drug.

Patients, methods, and results

Thirty patients (21 male, nine female; mean age 42 years, range 14-66) presented with bilateral nasal polyps and gave informed consent to participate in a double blind, placebo controlled study. After stratification for atopy they were randomised to receive either betamethasone sodium phosphate (Betnesol) or placebo nasal drops, two drops (50 µg betamethasone) into each nostril twice daily for four weeks. Patients were instructed to administer the drops in Moffat's position (head down and forwards; figure) and to remain in this position for three minutes after instillation of the drops.

The size of the polyps was assessed by rhinoscopy at the beginning and end of the study. Active anterior rhinomanometry (mercury NRS rhinomanometer interfaced to a BBC type B microcomputer) was used to measure the flow (ml/s) required to achieve 150 Pa (1.1 mm Hg) of pressure on inspiration and expiration in each nostril before and after treatment. Nasal airways resistance was calculated as pressure/flow.

After recording past history, including any surgery, the following investigations were performed in each patient: radiography of sinuses (occipitomeatal, occipitofrontal, lateral); immediate skin hypersensitivity tests to common allergens (two or more tests yielded positive reactions in 10 patients in the active treatment group and 11 patients in the placebo group); full blood count with differential white cell count; total serum IgE estimation; measurement of nasal mucociliary clearance by the modified saccharin method.

Nine of the 15 patients taking betamethasone drops and two of the 15 taking placebo responded with disappearance of visible nasal polyps. This difference was significant ($p < 0.05$; Mann-Whitney U test).

The inspiratory and expiratory nasal airways resistance of each nostril was combined to give a total score. In those taking active drops this score was improved by 50% or more in eight patients and by between 20% and 50% in three patients but remained unchanged in four. This response differed significantly ($p < 0.02$; Mann-Whitney U test) from that in the placebo group, in which improvement of between 20% and 50% occurred in four patients, scores remained unchanged in 10, and a deterioration of greater than 50% occurred in one.

No significant difference was found between responders and non-responders in respect of the other variables measured at the beginning of the study.

Head down and forwards position.

Comment

The failure of other studies to show that nasal polyps can be treated successfully with topical corticosteroids may be related to the poor distribution of spray or drops within the obstructed nose when administered in the conventional "head back" position. This is supported by studies showing that, after surgery to clear such obstructing nasal polyps, recurrence may be prevented by using topical corticosteroids.^{4,5}

Our findings show that nasal polyps can be successfully treated medically in a significant proportion of patients, thereby avoiding surgery. We suggest that this success is due to the administration of the topical corticosteroid nose drops in a position encouraging maximal exposure of the nasal and paranasal sinus mucosa to the drug. Nevertheless, we were unable to identify any discriminant for response or non-response to the drug in these patients.

- 1 Mygind N. The treatment of nasal polyposis with intranasal beclomethasone dipropionate aerosol. *Clin Allergy* 1975;**5**:159-64.
- 2 Deuschl H, Drettnner B. Nasal polyps treated by beclomethasone nasal aerosol. *Rhinology* 1977;**15**:17-23.
- 3 Mygind N. Topical steroid treatment for allergic rhinitis and allied conditions. *Clin Otolaryngol* 1982;**7**:343-52.
- 4 Virolainen E, Putiakka H. The effect of intranasal beclomethasone dipropionate on the recurrence of nasal polyps after ethmoidectomy. *Rhinology* 1980;**18**:9-18.
- 5 Karlsson G, Rundcrantz H. A randomised trial of intra-nasal beclomethasone dipropionate after nasal polypectomy. *Rhinology* 1982;**20**:144-8.

(Accepted 21 June 1985)

Nose Clinic and ENT Department, Brompton Hospital, London SW3

ROSEMARY CHALTON, FRCS, senior ENT registrar
IAN MACKAY, FRCS, consultant ENT surgeon and honorary senior lecturer

Host Defence Unit, Department of Medicine, Cardiothoracic Institute, London SW3 6HP

ROBERT WILSON, MA, MRCP, clinical lecturer
PETER COLE, FRCP, MRCPATH, reader and honorary consultant physician

Correspondence to: Dr Cole.